Copyright: ©Author(s) 2026.
World J Hepatol. Mar 27, 2026; 18(3): 112850
Published online Mar 27, 2026. doi: 10.4254/wjh.v18.i3.112850
Published online Mar 27, 2026. doi: 10.4254/wjh.v18.i3.112850
Table 2 Comparison among the groups studied regarding insulin-like growth factor 2, intestinal fatty-acid-binding protein, and interferon-gamma
| Markers | HCV-COVID-19 group | COVID group | HCV group | Control group | |||
| mean ± SD | P | mean ± SD | P | mean ± SD | P | mean ± SD | |
| IGF-2 (ng/L) | 121 ± 12.7 | < 0.0001 | 98.46 ± 10.25 | < 0.0001 | 77.91 ± 12.04 | < 0.0001 | 32.67 ± 10.62 |
| I-FABP (ng/L) | 132.42 ± 31 | < 0.0001 | 45.21 ± 8.46 | < 0.0001 | 33.16 ± 9 | < 0.0001 | 31.46 ± 9.04 |
| IFN-γ (ng/L) | 166.18 ± 41.86 | < 0.0001 | 116.81 ± 18.61 | < 0.0001 | 101 ± 14.41 | 0.315 | 95.23 ± 12.92 |
- Citation: Mohamed AA, Abdel-Hamid RM, Amin A, A Gawad EAH, Saed SM, Gaber DA, Ezz Al Arab M, El-Agawy W, AbuRahma MZA, Elosaily HH, Shaaban EE, Ismail SA, Sakr AA. Immunogenetic and molecular biomarkers in COVID-19 and hepatitis C virus infection: Evaluating the diagnostic potential of HLA (rs1131500), IGF-2, and I-FABP. World J Hepatol 2026; 18(3): 112850
- URL: https://www.wjgnet.com/1948-5182/full/v18/i3/112850.htm
- DOI: https://dx.doi.org/10.4254/wjh.v18.i3.112850